(MMS) Maximus - Ratings and Ratios
Consulting, Software, Call-Center, Assessment, Enrollment
Dividends
| Dividend Yield | 1.44% |
| Yield on Cost 5y | 1.81% |
| Yield CAGR 5y | 1.74% |
| Payout Consistency | 92.7% |
| Payout Ratio | 16.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.5% |
| Value at Risk 5%th | 36.0% |
| Relative Tail Risk | -10.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.48 |
| Alpha | 5.61 |
| CAGR/Max DD | 0.22 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.456 |
| Beta | 0.373 |
| Beta Downside | 0.247 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.37% |
| Mean DD | 9.18% |
| Median DD | 5.99% |
Description: MMS Maximus November 07, 2025
Maximus, Inc. (NYSE:MMS) is a global provider of outsourced government services organized into three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The Federal Services arm delivers business-process outsourcing, eligibility and enrollment, clinical and technology solutions-including advanced analytics, cybersecurity, and cloud modernization-for federal health and human-services programs. The U.S. Services segment focuses on multi-channel enrollment support, beneficiary outreach, and a suite of employment-service offerings such as case management and job-readiness programs. The Outside the U.S. segment extends similar business-process and technology solutions to international governments, covering health assessments, employment-service administration, and digital customer-service platforms.
Key recent metrics underline the company’s growth trajectory: FY 2023 revenue reached approximately $5.2 billion, up 8 % year-over-year, driven largely by expanding Medicaid and unemployment-benefits contracts; the operating margin held steady near 9 %, reflecting disciplined cost management amid higher labor costs. The backlog of signed contracts-estimated at $13 billion-provides a multi-year revenue runway, while FY 2024 guidance anticipates double-digit top-line growth, supported by increased federal spending on health-care modernization and state-level workforce-development initiatives. Macro-level, the sector benefits from a sustained policy trend toward outsourcing non-core government functions and from demographic pressures that raise demand for health-service eligibility processing.
For a deeper, data-driven view of Maximus’s valuation dynamics and scenario analysis, you may find the research tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (319.0m TTM) > 0 and > 6% of Revenue (6% = 325.9m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA -0.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.98% (prev 7.41%; Δ 1.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 429.4m > Net Income 319.0m (YES >=105%, WARN >=100%) |
| Net Debt (1.18b) to EBITDA (662.6m) ratio: 1.79 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (57.0m) change vs 12m ago -7.31% (target <= -2.0% for YES) |
| Gross Margin 22.86% (prev 23.18%; Δ -0.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 132.5% (prev 128.4%; Δ 4.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.29 (EBITDA TTM 662.6m / Interest Expense TTM 84.1m) >= 6 (WARN >= 3) |
Altman Z'' 3.24
| (A) 0.12 = (Total Current Assets 1.25b - Total Current Liabilities 765.2m) / Total Assets 4.07b |
| (B) 0.26 = Retained Earnings (Balance) 1.06b / Total Assets 4.07b |
| (C) 0.13 = EBIT TTM 528.9m / Avg Total Assets 4.10b |
| (D) 0.70 = Book Value of Equity 1.67b / Total Liabilities 2.40b |
| Total Rating: 3.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.70
| 1. Piotroski 6.0pt |
| 2. FCF Yield 6.06% |
| 3. FCF Margin 6.74% |
| 4. Debt/Equity 0.86 |
| 5. Debt/Ebitda 1.79 |
| 6. ROIC - WACC (= 6.59)% |
| 7. RoE 18.87% |
| 8. Rev. Trend 88.85% |
| 9. EPS Trend 79.14% |
What is the price of MMS shares?
Over the past week, the price has changed by -4.25%, over one month by +0.70%, over three months by -5.30% and over the past year by +18.77%.
Is MMS a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MMS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110 | 32% |
| Analysts Target Price | 110 | 32% |
| ValueRay Target Price | 87.5 | 4.9% |
MMS Fundamental Data Overview November 29, 2025
P/E Trailing = 15.6479
P/E Forward = 18.2482
P/S = 0.8945
P/B = 2.805
P/EG = 2.0716
Beta = 0.556
Revenue TTM = 5.43b USD
EBIT TTM = 528.9m USD
EBITDA TTM = 662.6m USD
Long Term Debt = 1.28b USD (from longTermDebt, last quarter)
Short Term Debt = 91.3m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.18b USD (from netDebt column, last quarter)
Enterprise Value = 6.04b USD (4.86b + Debt 1.44b - CCE 260.5m)
Interest Coverage Ratio = 6.29 (Ebit TTM 528.9m / Interest Expense TTM 84.1m)
FCF Yield = 6.06% (FCF TTM 366.2m / Enterprise Value 6.04b)
FCF Margin = 6.74% (FCF TTM 366.2m / Revenue TTM 5.43b)
Net Margin = 5.87% (Net Income TTM 319.0m / Revenue TTM 5.43b)
Gross Margin = 22.86% ((Revenue TTM 5.43b - Cost of Revenue TTM 4.19b) / Revenue TTM)
Gross Margin QoQ = 23.55% (prev 24.96%)
Tobins Q-Ratio = 1.48 (Enterprise Value 6.04b / Total Assets 4.07b)
Interest Expense / Debt = 1.55% (Interest Expense 22.4m / Debt 1.44b)
Taxrate = 25.06% (25.2m / 100.5m)
NOPAT = 396.4m (EBIT 528.9m * (1 - 25.06%))
Current Ratio = 1.64 (Total Current Assets 1.25b / Total Current Liabilities 765.2m)
Debt / Equity = 0.86 (Debt 1.44b / totalStockholderEquity, last quarter 1.67b)
Debt / EBITDA = 1.79 (Net Debt 1.18b / EBITDA 662.6m)
Debt / FCF = 3.23 (Net Debt 1.18b / FCF TTM 366.2m)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.84% (Net Income 319.0m / Total Assets 4.07b)
RoE = 18.87% (Net Income TTM 319.0m / Total Stockholder Equity 1.69b)
RoCE = 17.80% (EBIT 528.9m / Capital Employed (Equity 1.69b + L.T.Debt 1.28b))
RoIC = 12.55% (NOPAT 396.4m / Invested Capital 3.16b)
WACC = 5.96% (E(4.86b)/V(6.30b) * Re(7.39%) + D(1.44b)/V(6.30b) * Rd(1.55%) * (1-Tc(0.25)))
Discount Rate = 7.39% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.77%
[DCF Debug] Terminal Value 77.50% ; FCFE base≈372.9m ; Y1≈354.0m ; Y5≈338.5m
Fair Price DCF = 111.1 (DCF Value 6.05b / Shares Outstanding 54.5m; 5y FCF grow -6.60% → 3.0% )
EPS Correlation: 79.14 | EPS CAGR: 18.77% | SUE: -0.18 | # QB: 0
Revenue Correlation: 88.85 | Revenue CAGR: 3.69% | SUE: -0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.02 | Chg30d=+0.070 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-09-30): EPS=8.17 | Chg30d=+0.545 | Revisions Net=+2 | Growth EPS=+11.0% | Growth Revenue=+0.7%
EPS next Year (2027-09-30): EPS=8.68 | Chg30d=+0.500 | Revisions Net=+2 | Growth EPS=+6.2% | Growth Revenue=+5.0%
Additional Sources for MMS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle